MedPath

Vitamin D supplementation and breast cancer preventio

Phase 2
Conditions
Breast Cancer Survivour.
Registration Number
IRCT2017091736244N1
Lead Sponsor
Cancer Research Center, Shahid Beheshti University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
165
Inclusion Criteria

Patients with breast cancer including invasive or in situ carcinoma whose cancer was approved through pathological examination; Women aged 25-65 years; BMI between 25 to 35 kg/m2; not using 1000 IU daily or 50000 IU weekly or 300000 intramuscular injection of vitamin D supplement for at least 4 months before the study; not using dietary, herbal or omega-3 supplements during the intervention period; Patients were diagnosed with breast cancer at least 6 months prior the study and treatment protocols including surgery, radiotherapy and chemotherapy were completed.
Exclusion criteria:
History of malabsorption syndrome, calcium metabolism disorder, gastrointestinal, renal, inflammatory (sarcoidosis, etc.) and other endocrinological diseases; Treatment for weight reduction; high levels of plasma vitamin D

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Plasma vitamin D level. Timepoint: Baseline and post- intervention. Method of measurement: ELISA.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath